Examining the Relationship between Circulating CD4− CD8− Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy—Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma
Open Access
- 16 February 2021
- Vol. 10 (2), 406
- https://doi.org/10.3390/cells10020406
Abstract
Background: The role of circulating CD4−/CD8− double-negative T cells (DNTs) in the immune response to melanoma is poorly understood, as are the effects of checkpoint inhibitors on T cell subpopulations. Methods: We performed a basal and longitudinal assessment of circulating immune cells, including DNTs, in metastatic melanoma patients treated with checkpoint blockade in a single-center cohort, and examined the correlations levels of immune cells with clinical features and therapy outcomes. Results: Sixty-eight patients (48 ipilimumab, 20 PD1 inhibitors) were enrolled in the study. Our analysis indicated that better outcomes were associated with normal LDH, fewer than three metastatic sites, an ECOG performance status of 0, M1a stage, lower WBC and a higher lymphocyte count. The increase in lymphocyte count and decrease of DNTs were significantly associated with the achievement of an overall response. The median value of DNT decreased while the CD4+ and NK cells increased in patients that responded to treatment compare to those who did not respond to treatment. Conclusions: DNT cells change during treatment with checkpoint inhibitors and may be adept at sensing the immune response to melanoma. The complementary variation of DNT cells with respect to CD4+ and other immune actors may improve the reliability of lymphocyte assessment. Further investigation of DNT as a potential target in checkpoint inhibitor resistant melanoma is warranted.This publication has 37 references indexed in Scilit:
- Immunoregulatory CD4-CD8- T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancerFrontiers in Immunology, 2013
- Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directionsJournal of Molecular Cell Biology, 2012
- CD3+CD4−CD8− (double negative) T cells: Saviours or villains of the immune response?Biochemical Pharmacology, 2011
- Regulation of antigen-expressing dendritic cells by double negative regulatory T cellsEuropean Journal of Immunology, 2011
- Consequences of double negative regulatory T cell and antigen presenting cell interaction on immune response suppressionInternational Immunopharmacology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burdenBritish Journal of Haematology, 2009
- Characterization of MHC class-I restricted TCRαβ+ CD4− CD8− double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccinationCancer Immunology, Immunotherapy, 2008
- New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responsesBlood, 2006
- Isolation and characterization of human antigen-specific TCRαβ+ CD4-CD8- double-negative regulatory T cellsBlood, 2005